

4. (Twice Amended) A solid pharmaceutical composition according to claim 1, wherein said buffer system comprises at least one organic acid and/or at least one salt of an organic acid in association with at least one strong base and/or at least one salt of a strong base.

5. (Twice Amended) A solid pharmaceutical composition according to claim 4, wherein said organic acid is selected from the group consisting of citric, tartaric, malic, lactic, acetic, glutaric, benzoic and adipic acids.

6. (Twice Amended) A solid pharmaceutical composition according to claim 4, wherein said base comprises sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium carbonate, sodium hydroxide, potassium hydroxide, potassium bicarbonate or potassium carbonate.

7. (Twice Amended) A solid pharmaceutical composition according to claim 1, in the form of an effervescent solid galenical preparation.

8. (Twice Amended) A solid pharmaceutical composition according to claim 1, in the form of an effervescent tablet.

9. (Twice Amended) A solid pharmaceutical composition according to claim 9, in the form of an

effervescent tablet containing citric acid and sodium bicarbonate.

BS  
10. (Twice Amended) Process for the preparation of a solid pharmaceutical composition according to claim 1, comprising formulating the phloroglucinol in a solid form with a solid buffer system which, when said solid composition is placed in an aqueous medium, results in a pH between pH 3 and pH 7.

Please add the following new claims:

11. (New) A method for administration of phloroglucinol to a human or animal in need thereof, comprising formulating the phloroglucinol in a composition in combination with a buffer system capable of buffering the composition when placed in an aqueous medium to a pH between 3 and 7, and administering the composition to a human or animal.

Bu  
12. (New) The method of claim 11, wherein the pH is between 4 and 6.

13. (New) The method of claim 11, wherein the phloroglucinol is formulated in a solid composition.

14. (New) The method of claim 11, wherein the phloroglucinol is formulated in a liquid composition.

15. (New) The method of claim 11, wherein the composition is administered in liquid form.

16. (New) The method of claim 15, wherein the liquid form in effervescent.

17. (New) The method of claim 11, wherein the composition is administered in solid form.

18. (New) The method of claim 17, wherein the solid form is a tablet or gelatin capsule.

19. (New) The method of claim 11, wherein said buffer system comprises at least one organic acid and/or at least one salt of an organic acid in association with at least one strong base and/or at least one salt of a strong base.

20. (New) The method of claim 19, wherein said organic acid is selected from the group consisting of citric, tartaric, malic, lactic, acetic, glutaric, benzoic and adipic acids.

21. (New) The method of claim 19, wherein said base comprises sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium carbonate, sodium hydroxide, potassium hydroxide, potassium bicarbonate or potassium carbonate.

22. (New) A dosage form for pharmaceutical administration of phloroglucinol, comprising a therapeutically effective amount of phloroglucinol in combination with a buffer system which is capable, when the dosage form is placed

in an aqueous medium, of maintain<sup>705</sup> the medium at a pH of between 3 and 7.

23. (New) The dosage form of claim 22 wherein the buffer is capable of maintaining a pH of between 4 and 6.

24. (New) The dosage form of claim 22, which is a tablet or gelatin capsule.

25. (New) The dosage form of claim 22, which is an effervescent tablet or granules.

26. (New) The dosage form of claim 23, wherein the buffer system comprises citric acid and sodium bicarbonate.

27. (New) The dosage form of claim 22, which is in the form of a liquid.

28. (New) The dosage form of claim 22, wherein the therapeutically effective amount is about 80 mg.